Thrombolysis with alteplase for acute ischemic stroke: Review of SITS-MOST and other phase IV studies

Expert Review of Neurotherapeutics

Volumn 7, Issue 7, 2007, Pages 783-788

  Külkens, Sonja ^a   Hacke, Werner ^a  

^a Department of Neurology ^*  (Germany)

Author keywords

Alteplase; Phase IV study; Stroke; Stroke treatment; Thrombolysis

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL;

AGED; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS, PHASE IV; FIBRINOLYTIC AGENTS; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 34447128746     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.7.783     Document Type: Article

References (12)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333(24), 1581-1587 (1995). •• Key paper for approval of alteplase in acute ischemic stroke patients
2. Clark WM, Wissman S, Albers GW et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282(21), 2019-2026 (1999).
3. Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 352(9136), 1245-1251 (1998).
4. Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute stroke. JAMA 274, 1017-1025 (1995).
5. Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363(9411), 768-774 (2004). •• Combined analysis of all randomized trials for alteplase in acute ischemic stroke patients, which clearly demonstrates the time-dependent effect.
6. Wahlgren N, Ahmed N, Davalos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369(9558), 275-282 (2007).
7. Wardlaw JM, Sandercock PA, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 34(6), 1437-1442 (2003).
8. Larrue V, von Kummer R, del Zoppo G et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 28(5), 957-960 (1997).
9. Berger C, Fiorelli M, Steiner T et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 32(6), 1330-1335 (2001).
10. NINDS-Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 98, 2109-2118 (1997).
11. Albers GW, Bates VE, Clark WM et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283(9), 1145-1150 (2000).
12. Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172(10), 1307-1312 (2005).